Exelixis Inc Interest Receivable
Exelixis Inc (EXEL) had Interest Receivable of $12.40 million as of 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:InterestReceivable · last filed 2026-08-05
- 2026-07-03: Interest Receivable $12.40M.
- 2026-04-03: Interest Receivable $10.50M.
- 2026-01-02: Interest Receivable $12.40M.
- 2025-10-03: Interest Receivable $11.40M.
| Period end | Interest Receivable |
|---|---|
| 2026-07-03 | $12.40M 10-Q · filed 2026-08-05 |
| 2026-04-03 | $10.50M 10-Q · filed 2026-05-05 |
| 2026-01-02 | $12.40M 10-Q · filed 2026-08-05 |
| 2025-10-03 | $11.40M 10-Q · filed 2025-11-04 |
| 2025-07-04 | $13.90M 10-Q · filed 2025-07-28 |
| 2025-04-04 | $12.80M 10-Q · filed 2025-05-13 |
| 2025-01-03 | $14.90M 10-K · filed 2026-02-10 |
| 2024-09-27 | $13.00M 10-Q · filed 2024-10-29 |
| 2024-06-28 | $11.10M 10-Q · filed 2024-08-06 |
| 2024-03-29 | $11.90M 10-Q · filed 2024-04-30 |
| 2023-12-29 | $13.10M 10-K · filed 2025-02-11 |
| 2023-09-29 | $12.10M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $11.40M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $10.10M 10-Q · filed 2023-05-09 |
| 2022-12-30 | $7.30M 10-K · filed 2024-02-06 |
| 2022-09-30 | $4.80M 10-Q · filed 2022-11-01 |
| 2022-07-01 | $3.60M 10-Q · filed 2022-08-09 |
| 2022-04-01 | $2.60M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $2.90M 10-K · filed 2023-02-07 |
| 2021-10-01 | $2.60M 10-Q · filed 2021-11-02 |
| 2021-07-02 | $3.30M 10-Q · filed 2021-08-05 |
| 2021-04-02 | $3.60M 10-Q · filed 2021-05-06 |
| 2021-01-01 | $4.50M 10-K · filed 2022-02-18 |
| 2020-10-02 | $4.50M 10-Q · filed 2020-11-05 |
| 2020-07-03 | $5.30M 10-Q · filed 2020-08-06 |
| 2020-04-03 | $5.40M 10-Q · filed 2020-05-05 |
| 2020-01-03 | $6.20M 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |